<DOC>
	<DOCNO>NCT01470599</DOCNO>
	<brief_summary>The study hypothesis establish safety tolerability long-term open-label ( OL ) CP-690,550 therapy subject Crohn 's disease .</brief_summary>
	<brief_title>A Open-Label Study Of CP-690,550 As Long-Term Therapy ( 48 Weeks ) In Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects complete 26week maintenance treatment A3921084 study subject withdraw early due A3921084 study treatment failure ( see Appendix 5 ) . Women childbearing potential must test negative pregnancy prior study enrolment . Sexually active female childbearing potential require use adequate contraceptive method study period completion followup procedure . No specific contraceptive measure require male subject study participation . Subjects discontinue due protocol violation ( ) ( determine Sponsor ) A3921084 study . Subjects discontinue A3921084 study due adverse event . Subjects likely require nonelective surgery surgery require overnight stay ( exception minor day outpatient procedure interfere study drug dosing ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>